{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T20:04:04Z","timestamp":1781035444354,"version":"3.54.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bloodreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.blre.2014.09.004","type":"journal-article","created":{"date-parts":[[2014,9,16]],"date-time":"2014-09-16T07:57:28Z","timestamp":1410854248000},"page":"25-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Blocking tumor escape in hematologic malignancies: The anti-PD-1 strategy"],"prefix":"10.1016","volume":"29","author":[{"given":"Locke J.","family":"Bryan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo I.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2014.09.004_bb0005","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nrc1782","article-title":"Paradoxical roles of the immune system during cancer development","volume":"6","author":"de Visser","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.blre.2014.09.004_bb0010","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/35074122","article-title":"IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity","volume":"410","author":"Shankaran","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.blre.2014.09.004_bb0015","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1182\/blood-2008-03-077974","article-title":"Graft-versus-leukemia effects of transplantation and donor lymphocytes","volume":"112","author":"Kolb","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2014.09.004_bb0020","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/152581602753658457","article-title":"Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation","volume":"11","author":"Slavin","year":"2002","journal-title":"J Hematother Stem Cell Res"},{"key":"10.1016\/j.blre.2014.09.004_bb0025","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.2174\/1381612033454333","article-title":"Cytotoxic T cell responses against immunoglobulin in malignant and normal B cells: implications for tumor immunity and autoimmunity","volume":"9","author":"Gricks","year":"2003","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.blre.2014.09.004_bb0030","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1517\/14712598.5.4.463","article-title":"Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control?","volume":"5","author":"Rivoltini","year":"2005","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.blre.2014.09.004_bb0035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semcancer.2005.07.008","article-title":"Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention","volume":"16","author":"Whiteside","year":"2006","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.blre.2014.09.004_bb0040","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.blre.2014.09.004_bb0045","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"key":"10.1016\/j.blre.2014.09.004_bb0050","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/ijc.21775","article-title":"Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro","volume":"119","author":"Blank","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.blre.2014.09.004_bb0055","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2014.09.004_bb0060","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.blre.2014.09.004_bb0065","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.imlet.2005.09.007","article-title":"Co-inhibitory role of T-cell-associated B7-H1 and B7-DC in the T-cell immune response","volume":"102","author":"Seo","year":"2006","journal-title":"Immunol Lett"},{"key":"10.1016\/j.blre.2014.09.004_bb0070","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1038\/bjc.2013.117","article-title":"Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer","volume":"108","author":"Quezada","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.blre.2014.09.004_bb0075","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.it.2006.02.001","article-title":"The PD-1\u2013PD-L pathway in immunological tolerance","volume":"27","author":"Okazaki","year":"2006","journal-title":"Trends Immunol"},{"key":"10.1016\/j.blre.2014.09.004_bb0080","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1128\/JVI.02844-06","article-title":"Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection","volume":"81","author":"Boni","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.blre.2014.09.004_bb0085","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature05115","article-title":"PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression","volume":"443","author":"Day","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.blre.2014.09.004_bb0090","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jhep.2007.12.014","article-title":"Restoration of HCV-specific T cell functions by PD-1\/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment","volume":"48","author":"Urbani","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.blre.2014.09.004_bb0095","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1089\/vim.2011.0096","article-title":"PD-1 expression on natural killer cells and CD8(+) T cells during chronic HIV-1 infection","volume":"25","author":"Norris","year":"2012","journal-title":"Viral Immunol"},{"key":"10.1016\/j.blre.2014.09.004_bb0100","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.4049\/jimmunol.176.5.3000","article-title":"Expression of B7-H1 on gastric epithelial cells: its potential role in regulating T cells during Helicobacter pylori infection","volume":"176","author":"Das","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2014.09.004_bb0105","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2174\/187153008786848349","article-title":"The role of negative costimulators during parasitic infections","volume":"8","author":"Lepenies","year":"2008","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"10.1016\/j.blre.2014.09.004_bb0110","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1200\/JCO.2013.51.7680","article-title":"Restoring antitumor immunity via PD-1 blockade after autologous stem-cell transplantation for diffuse large B-cell lymphoma","volume":"31","author":"Jacobsen","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2014.09.004_bb0115","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2014.09.004_bb0120","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2014.09.004_bb0125","doi-asserted-by":"crossref","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.blre.2014.09.004_bb0130","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/0008-5472.1089.65.3","article-title":"Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity","volume":"65","author":"Hirano","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2014.09.004_bb0135","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2006-10-051482","article-title":"Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway","volume":"110","author":"Liu","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2014.09.004_bb0140","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/01.pas.0000209855.28282.ce","article-title":"Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma","volume":"30","author":"Dorfman","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.blre.2014.09.004_bb0145","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1182\/blood-2006-12-064360","article-title":"RNA fingerprints provide direct evidence for the inhibitory role of TGFbeta and PD-1 on CD4+ T cells in Hodgkin lymphoma","volume":"110","author":"Chemnitz","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2014.09.004_bb0150","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1002\/ijc.23042","article-title":"Augmented expression of programmed death-1 in both neoplastic and non-neoplastic CD4+ T-cells in adult T-cell leukemia\/lymphoma","volume":"121","author":"Shimauchi","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.blre.2014.09.004_bb0155","doi-asserted-by":"crossref","first-page":"5708","DOI":"10.1158\/1078-0432.CCR-04-2672","article-title":"Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia","volume":"11","author":"Tamura","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2014.09.004_bb0160","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1084\/jem.20031074","article-title":"Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma","volume":"198","author":"Rosenwald","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2014.09.004_bb0165","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.2008.18.0513","article-title":"High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma","volume":"27","author":"Carreras","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2014.09.004_bb0170","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3324\/haematol.11702","article-title":"Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma","volume":"93","author":"Tzankov","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2014.09.004_bb0175","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.humpath.2007.11.012","article-title":"Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma\/chronic lymphocytic leukemia","volume":"39","author":"Xerri","year":"2008","journal-title":"Hum Pathol"},{"key":"10.1016\/j.blre.2014.09.004_bb0180","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/j.humpath.2009.03.025","article-title":"Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival","volume":"40","author":"Muenst","year":"2009","journal-title":"Hum Pathol"},{"key":"10.1016\/j.blre.2014.09.004_bb0185","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/intimm\/dxm057","article-title":"PD-1 and PD-1 ligands: from discovery to clinical application","volume":"19","author":"Okazaki","year":"2007","journal-title":"Int Immunol"},{"key":"10.1016\/j.blre.2014.09.004_bb0190","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1155\/2010\/404069","article-title":"Diagnostic and prognostic utility of PD-1 in B cell lymphomas","volume":"29","author":"Muenst","year":"2010","journal-title":"Dis Markers"},{"key":"10.1016\/j.blre.2014.09.004_bb0195","series-title":"ASH 55th Annual Meeting","article-title":"PD-1 expression defines Two distinct T-cell subpopulations that differentially impact patient outcomes in follicular lymphoma","author":"Yang","year":"2013"},{"key":"10.1016\/j.blre.2014.09.004_bb0200","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.361.361","article-title":"Blood soluble PD-L1 protein in aggressive diffuse large B-cell lymphoma impacts patient's overall survival","author":"Fest","year":"2013"},{"key":"10.1016\/j.blre.2014.09.004_bb0205","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1189\/jlb.1212621","article-title":"At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy","volume":"94","author":"Intlekofer","year":"2013","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.blre.2014.09.004_bb0210","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.blre.2014.09.004_bb0215","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2012.48.3685","article-title":"Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial","volume":"31","author":"Armand","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2014.09.004_bb0220","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(13)70551-5","article-title":"Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial","volume":"15","author":"Westin","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2014.09.004_bb0225","first-page":"5793","article-title":"A monoclonal antibody against a human B lymphoblastoid cell line induces tumor regression in mice","volume":"54","author":"Hardy","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2014.09.004_bb0230","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0165-2478(99)00081-4","article-title":"Activation of lymphocytes by BAT and anti CTLA-4: comparison of binding to T and B cells","volume":"69","author":"Raiter","year":"1999","journal-title":"Immunol Lett"},{"key":"10.1016\/j.blre.2014.09.004_bb0235","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1158\/1078-0432.CCR-07-4079","article-title":"Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies","volume":"14","author":"Berger","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2014.09.004_bb0240","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/bjh.12176","article-title":"Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era","volume":"160","author":"Armand","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2014.09.004_bb0245","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2014.09.004_bb0250","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2014.09.004_bb0255","series-title":"2013 ASCO Annual Meeting. Chicago, IL","article-title":"Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in preclinical models","author":"Selby","year":"2013"},{"key":"10.1016\/j.blre.2014.09.004_bb0260","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2014.09.004_bb0265","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2014.09.004_bb0270","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","article-title":"Targeting the PD-1\/B7-H1(PD-L1) pathway to activate anti-tumor immunity","volume":"24","author":"Topalian","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.blre.2014.09.004_bb0275","series-title":"ASCO Annual Meeting 2013","article-title":"Clinical and pharmacodynamics (PD) results of a Phase I trial with AMP-224 (B7-DC Fc) that binds to the PD-1 receptor","author":"Infante","year":"2013"},{"key":"10.1016\/j.blre.2014.09.004_bb0280","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.4049\/jimmunol.1103085","article-title":"B7-DC-Ig enhances vaccine effect by a novel mechanism dependent on PD-1 expression level on T cell subsets","volume":"189","author":"Mkrtichyan","year":"2012","journal-title":"J Immunol"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X14000733?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X14000733?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,16]],"date-time":"2023-07-16T15:31:13Z","timestamp":1689521473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X14000733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0268960X14000733"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2014.09.004","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blocking tumor escape in hematologic malignancies: The anti-PD-1 strategy","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2014.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}